Answers are grounded in this paper and cite their sources.
OBJECTIVE: Biliary atresia (BA) is a rare and potentially fatal cholangiopathy affecting infants. The primary treatment approach for BA is Kasai hepatoportoenterostomy (KP); however, even with KP, many patients still require liver transplantation (LT). The objective of this systematic literature review (SLR) was to describe epidemiology, natural history, and native liver survival (NLS), as well as the humanistic and economic burden, in patients with BA in the United States (US). METHODS: Embase and MEDLINE searches were performed; US-based, English-language publications from 2014 to 2024 were included. Additional searches were conducted for non-peer-reviewed publications, including congress abstracts. The SLR was conducted per Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. RESULTS: Across epidemiology, natural history, and NLS, 38/3485 records were included; for the humanistic and economic burden outcomes, 16/1471 records were included. Sample sizes ranged from 10 to 4306 patients, and BA prevalence was 6.5-6.8 per 100,000 live births. Complications of BA included various hepatic, cardiovascular, and renal abnormalities, among others. Post-transplant graft survival rates ranged from 86.0%-96.0% and 79.0%-97.0% at 1 and 5 years post-LT, respectively. BA was also associated with high healthcare resource utilization (HCRU) and disease costs. Overall, sample heterogeneity and study design differences made comparisons across studies difficult. CONCLUSIONS: Although there are limited data on BA outcomes in the US, and the published BA studies are heterogeneous, this SLR reveals a substantial burden due to BA-related care and complications. Additionally, data on HCRU and costs highlight the unmet need for additional management and research in BA.
No takes yet. Share an insight, caveat, or question.
Rabbani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: